Monthly Archives: May 2020
RBC Capital Keeps Their Hold Rating on Laurentian Bank (LRCDF)
In a report issued on May 29, Darko Mihelic from RBC Capital maintained a Hold rating on Laurentian Bank (LRCDF – Research Report), with a price target of C$33.00. The company’s shares closed last Tuesday at $22.30. According to TipRanks.com,
Analysts Offer Insights on Healthcare Companies: Evofem Biosciences (NASDAQ: EVFM) and Argenx Se (NASDAQ: ARGX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evofem Biosciences (EVFM – Research Report) and Argenx Se (ARGX – Research Report) with bullish sentiments. Evofem Biosciences (EVFM) RBC Capital analyst
Paragon ID SA (PAGDF) Gets a Hold Rating from Kepler Capital
In a report issued on May 29, Douglas Lindahl from Kepler Capital maintained a Hold rating on Paragon ID SA (PAGDF – Research Report), with a price target of EUR33.00. The company’s shares closed last Thursday at $33.03. According to
Kepler Capital Sticks to Their Buy Rating for DO & CO Aktiengesellschaft (DOCOF)
In a report issued on May 29, Julien Richer from Kepler Capital maintained a Buy rating on DO & CO Aktiengesellschaft (DOCOF – Research Report), with a price target of EUR82.00. The company’s shares closed last Tuesday at $48.36, close
Allogene Therapeutics (ALLO) Receives a Buy from Oppenheimer
Oppenheimer analyst Mark Breidenbach assigned a Buy rating to Allogene Therapeutics (ALLO – Research Report) yesterday and set a price target of $55.00. The company’s shares closed last Friday at $48.16. According to TipRanks.com, Breidenbach is a 5-star analyst with
Aegis Capital Reaffirms Their Buy Rating on SCYNEXIS (SCYX)
In a report issued on April 23, Nathan Weinstein from Aegis Capital reiterated a Buy rating on SCYNEXIS (NASDAQ: SCYX), with a price target of $4.50. The company’s shares closed last Friday at $0.75. Currently, the analyst consensus on SCYNEXIS
